{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:03:10Z","timestamp":1790794990321,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,4,14]],"date-time":"2008-04-14T00:00:00Z","timestamp":1208131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:p>Midkine (MK) is a secreted heparin\u2010binding growth factor. Several types of human cancer have increased MK expression with elevated serum levels. The purpose of this study was to determine whether MK was expressed in endometrial carcinoma and to evaluate the clinicopathological significance of serum MK in patients with endometrial carcinoma. Immunohistochemical expression of MK was evaluated in 85 endometrial carcinoma samples and 33 controls. MK expression was significantly higher in the carcinomas than in normal endometrium (<jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00.001). Interestingly, MK expression was highest at the margins of invasion and low in the superficial areas of the tumor samples. Using ELISA, we compared serum MK concentration in 120 endometrial carcinoma patients with the concentration in 46 patients with benign gynecologic tumors. Serum MK value in patients with cancer was significantly higher than that in the patients with benign diseases (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.01). Patients with positive lymph node metastasis or recurrence, or cancer death, had a higher serum MK level (<jats:italic>P\u00a0=<\/jats:italic>\u00a00.008,<jats:italic>P<\/jats:italic>\u00a0=\u00a00.009, respectively). In conclusion, MK immunoreactivity in endometrial carcinoma is significantly higher than in normal endometrium. Additionally, preoperative serum MK levels are significantly correlated with prognosis and the presence of lymph node metastasis. Thus, MK may be a useful serum biomarker for identifying high risk patients of endometrial carcinoma. (<jats:italic>Cancer Sci<\/jats:italic>2008; 99: 1125\u20131130)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2008.00796.x","type":"journal-article","created":{"date-parts":[[2008,4,14]],"date-time":"2008-04-14T22:05:17Z","timestamp":1208210717000},"page":"1125-1130","source":"Crossref","is-referenced-by-count":26,"title":["Midkine and its clinical significance in endometrial carcinoma"],"prefix":"10.1111","volume":"99","author":[{"given":"Kojiro","family":"Tanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyo","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Ikematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Niikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kadomatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin\u2010ichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Yaegashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,4,14]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.1.43"},{"issue":"10","key":"e_1_2_6_3_2","first-page":"243","article-title":"Epidemiology of endometrial carcinoma","volume":"62","author":"Jobo T","year":"2004","journal-title":"Nippon Rinsho"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(88)80505-9"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(90)91189-Y"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(05)80255-4"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.58"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1046\/j.1471-4159.1999.02084.x","article-title":"Midkine inhibits caspase\u2010dependent apoptosis via the activation of mitogen\u2010activated protein kinase and phosphatidylinositol 3\u2010kinase in cultured neurons","volume":"73","author":"Owada K","year":"1999","journal-title":"J Neurochem"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1242\/jcs.115.13.2659","article-title":"Midkine, a heparin\u2010binding growth factor, promotes growth and glycosaminoglycan synthesis of endothelial cells through its action on smooth muscle cells in an artificial blood vessel model","volume":"115","author":"Sumi Y","year":"2002","journal-title":"J Cell Sci"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb\/9.5.463"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i13.2006"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690030"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00237-8"},{"key":"e_1_2_6_15_2","first-page":"2515","article-title":"The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers","volume":"56","author":"O\u2019Brien T","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000012039"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(97)00619-8"},{"key":"e_1_2_6_18_2","first-page":"1792","article-title":"Differential expression of pleiotrophin and midkine in advanced neuroblastomas","volume":"55","author":"Nakagawara A","year":"1995","journal-title":"Cancer Res"},{"key":"e_1_2_6_19_2","first-page":"1281","article-title":"A new family of heparin\u2010binding growth differentiation factors: increased midkine expression in Wilms\u2019 tumor and other human carcinomas","volume":"53","author":"Tsutsui J","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1339"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2003.tb01494.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2005.00001.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600938"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2002-3-7-research0034"},{"key":"e_1_2_6_25_2","first-page":"8486","article-title":"Antisense oligodeoxynucleotide targeted to Midkine, a heparin\u2010binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells","volume":"61","author":"Takei Y","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_26_2","first-page":"1814","article-title":"An angiogenic role for the neurokines midkine and pleiotrophin in tumourigenesis","volume":"57","author":"Choudhuri R","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a022604"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M005911200"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-006-0180-y"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2006.09.004"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603879"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dem037"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.8.2738"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.placenta.2007\/09.009"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/13547500701192470"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901015)60:8 <2035::AID-CNCR2820601515>3.0.CO;2-8"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67063-8"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2008.00796.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2008.00796.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T01:28:15Z","timestamp":1708824495000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2008.00796.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,14]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1349-7006.2008.00796.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2008.00796.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,14]]}}}